September 14, 2016

Bayer and Monsanto to Create a Global Leader in Agriculture

Realizes a shared vision of integrated agricultural offerings, delivering enhanced solutions for growers and creates a leading innovation engine for the next generation of farming / USD 128 per share in all-cash transaction, represents 44 percent premium to Monsanto shareholders and an aggregate value of USD 66 billion / Significant value creation with expected annual synergies of approximately USD 1.5 billion after year three; plus additional synergies from integrated solutions in future years / Bayer shareholders expected to benefit from accretion to core EPS in the first full year after closing and double-digit percentage accretion in the third full year / Committed to retaining strong presence in the U.S. with the combined business' global Seeds & Traits and North American commercial headquarters in St. Louis
Leverkusen / St. Louis, September 14, 2016 - Bayer and Monsanto today announced
that they signed a definitive merger agreement under which Bayer will acquire
Monsanto for USD 128 per share in an all-cash transaction. Monsanto's Board of
Directors, Bayer's Board of Management and Bayer's Supervisory Board have
unanimously approved the agreement. Based on Monsanto's closing share price on
May 9, 2016, the day before Bayer's first written proposal to Monsanto, the
offer represents a premium of 44 percent to that price.

"We are pleased to announce the combination of our two great organizations.
This represents a major step forward for our Crop Science business and
reinforces Bayer's leadership position as a global innovation driven Life
Science company with leadership positions in its core segments, delivering
substantial value to shareholders, our customers, employees and society at
large," said Werner Baumann, CEO of Bayer AG.

"Today's announcement is a testament to everything we've achieved and the value
that we have created for our stakeholders at Monsanto. We believe that this
combination with Bayer represents the most compelling value for our
shareowners, with the most certainty through the all-cash consideration," said
Hugh Grant, Chairman and Chief Executive Officer of Monsanto.

Enhanced Solutions for Growers

This transaction brings together two different, but highly complementary
businesses. The combined business will benefit from Monsanto's leadership in
Seeds & Traits and Climate Corporation platform along with Bayer's broad Crop
Protection product line across a comprehensive range of indications and crops
in all key geographies. As a result, growers will benefit from a broad set of
solutions to meet their current and future needs, including enhanced solutions
in seeds and traits, digital agriculture, and crop protection.

The combination also brings together both companies' leading innovation
capabilities and R&D technology platforms, with an annual pro-forma R&D budget
of approximately EUR 2.5 billion. Over the mid to long-term, the combined
business will be able to accelerate innovation and provide customers with
enhanced solutions and an optimized product suite based on analytical agronomic
insight supported by Digital Farming applications. These are expected to result
in significant and lasting benefits for farmers: from improved sourcing and
increased convenience to higher yield, better environmental protection and
sustainability.

"The agriculture industry is at the heart of one of the greatest challenges of
our time: how to feed an additional 3 billion people in the world by 2050 in an
environmentally sustainable way. It has been both companies' belief that this
challenge requires a new approach that more systematically integrates expertise
across Seeds, Traits and Crop Protection including Biologicals with a deep
commitment to innovation and sustainable agriculture practices," said Liam
Condon, member of the Board of Management of Bayer AG and head of the Crop
Science Division.

"We are entering a new era in agriculture - one with significant challenges
that demand new, sustainable solutions and technologies to enable growers to
produce more with less. This combination with Bayer will deliver just that - an
innovation engine that pairs Bayer's crop protection portfolio with our
world-class seeds and traits and digital agriculture tools to help growers
overcome the obstacles of tomorrow. Together Monsanto and Bayer will build on
our proud tradition and respective track records of innovation in the
agriculture industry, delivering a more comprehensive and broader set of
solutions to growers," said Grant.

Value Creation

Pro forma sales of the combined agricultural business amounted to EUR 23
billion in calendar year 2015. The combined company will be well positioned to
participate in the agricultural industry with significant long-term growth
potential. Beyond the attractive long term value creation potential of the
combination, Bayer expects the transaction to provide its shareholders with
accretion to core EPS (earnings per share) in the first full year after closing
and a double-digit percentage accretion in the third full year. Bayer has
confirmed sales and cost synergies assumptions in due diligence and expects
annual EBITDA contributions from total synergies of approximately USD 1.5
billion after year three, plus additional synergies from integrated solutions
in future years.

Financing and Closing Conditions

Bayer intends to finance the transaction with a combination of debt and equity.
The equity component of approximately USD 19 billion is expected to be raised
through an issuance of mandatory convertible bonds and through a rights issue
with subscription rights. Bridge financing for USD 57 billion is committed by
BofA Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and JP Morgan.

Bayer has a proven track record of disciplined deleveraging after large
acquisitions and believes that the strong cash flows of the combined business
will contribute to improving its financial profile. Bayer targets an investment
grade credit rating post-closing and is committed to the single "A" credit
rating category over the long-term.

The acquisition is subject to customary closing conditions, including Monsanto
shareholder approval of the merger agreement and receipt of required regulatory
approvals. Closing is expected by the end of 2017. The companies will work
diligently with regulators to ensure a successful closing. In addition, Bayer
has committed to a USD 2 billion reverse antitrust break fee, reaffirming its
confidence that it will obtain the necessary regulatory approvals.

Headquarters and Employees

The combined agriculture business will have its global Seeds & Traits and North
American commercial headquarters in St. Louis, Missouri, its global Crop
Protection and overall Crop Science headquarters in Monheim, Germany, and an
important presence in Durham, North Carolina, as well as many other locations
throughout the U.S. and around the world. The Digital Farming activities for
the combined business will be based in San Francisco, California.

"This combination is a great opportunity for employees, who will be at the
forefront of innovation in our sector. This transaction also enhances Bayer's
strong commitment to the U.S., building on our 150-year history with operations
across 25 states employing more than 12,000 people in the country. I am
convinced that Monsanto will flourish as part of one of the most respected and
trusted companies in the world," said Baumann.

Bayer has extensive experience in successfully integrating acquisitions from a
business, geographic and cultural perspective, and remains committed to its
strong culture of innovation, sustainability and social responsibility.

Advisors to the Transaction

BofA Merrill Lynch and Credit Suisse are acting as lead financial advisors and
structuring banks to Bayer in addition to providing committed financing for the
transaction; Rothschild has been retained as an additional financial advisor to
Bayer. Bayer's legal advisors are Sullivan & Cromwell LLP (M&A) and Allen &
Overy LLP (Financing).

Morgan Stanley & Co. and Ducera Partners are acting as financial advisors, and
Wachtell, Lipton, Rosen & Katz is acting as legal advisor to Monsanto.
?
Note:

Further information is available on the internet at: www.advancingtogether.com


- Statements of Werner Baumann and Hugh Grant as video and script (until
approx. 2:30 p.m. CEST / 8:30 a.m. EDT)
- Slides for the Investor Conference Call (until approx. 2:00 p.m. CEST / 8:00
a.m. EDT)
- Live webcast of the Investor Conference Call (from approx. 2:00 p.m. CEST /
8:00 a.m. EDT)
- Slides for the Media Conference Call (until approx. 3:30 p.m. CEST / 9:30
a.m. EDT)
- Speech and embedded slides for the Media Conference Call (from approx. 3:30
p.m. CEST / 9:30 a.m. EDT)
- Live webcast of the Media Conference Call (from approx. 3:30 p.m. CEST / 9:30
a.m. EDT)


Transcripts and audio recordings of all conference calls will be available
afterwards.


Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2015, the Group
employed around 117,000 people and had sales of EUR 46.3 billion. Capital
expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com.
?

About Monsanto Company


Monsanto is committed to bringing a broad range of solutions to help nourish
our growing world. We produce seeds for fruits, vegetables and key crops - such
as corn, soybeans, and cotton - that help farmers have better harvests while
using water and other important resources more efficiently. We work to find
sustainable solutions for soil health, help farmers use data to improve farming
practices and conserve natural resources, and provide crop protection products
to minimize damage from pests and disease. Through programs and partnerships,
we collaborate with farmers, researchers, nonprofit organizations, universities
and others to help tackle some of the world's biggest challenges. To learn more
about Monsanto, our commitments and our more than 20,000 dedicated employees,
please visit: discover.monsanto.com and monsanto.com. Follow our business on
Twitter® at twitter.com/MonsantoCo on the company blog, Beyond the Rows® at
monsantoblog.com or subscribe to our News Release RSS Feed.


Cautionary Statements Regarding Forward-Looking Information
Certain statements contained in this communication may constitute "forward-
looking statements." Actual results could differ materially from those
projected or forecast in the Forward-looking statements
. The factors that could
cause actual results to differ materially include the following: the risk that
Monsanto Company's ("Monsanto") stockholders do not approve the transaction;
uncertainties as to the timing of the transaction; the possibility that the
parties may be unable to achieve expected synergies and operating efficiencies
in the merger within the expected timeframes or at all and to successfully
integrate Monsanto's operations into those of Bayer Aktiengesellschaft
("Bayer"); such integration may be more difficult, time-consuming or costly
than expected; revenues following the transaction may be lower than expected;
operating costs, customer loss and business disruption (including, without
limitation, difficulties in maintaining relationships with employees,
customers, clients or suppliers) may be greater than expected following the
transaction; the retention of certain key employees at Monsanto; risks
associated with the disruption of management's attention from ongoing business
operations due to the transaction; the conditions to the completion of the
transaction may not be satisfied, or the regulatory approvals required for the
transaction may not be obtained on the terms expected or on the anticipated
schedule; the parties' ability to meet expectations regarding the timing,
completion and accounting and tax treatments of the merger; the impact of
indebtedness incurred by Bayer in connection with the transaction and the
potential impact on the rating of indebtedness of Bayer; the effects of the
business combination of Bayer and Monsanto, including the combined company's
future financial condition, operating results, strategy and plans; other
factors detailed in Monsanto's Annual Report on Form 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC") for the fiscal year ended August
31, 2015 and Monsanto's other filings with the SEC, which are available at
http://www.sec.gov and on Monsanto's website at www.monsanto.com; and other
factors discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. Bayer and Monsanto assume no obligation to update the
information in this communication, except as otherwise required by law. Readers
are cautioned not to place undue reliance on these forward-looking statements
that speak only as of the date hereof.
?

Additional Information and Where to Find It
This communication relates to the proposed merger transaction involving
Monsanto and Bayer. In connection with the proposed merger, Monsanto and Bayer
intend to file relevant materials with the SEC, including Monsanto's proxy
statement on Schedule 14A (the "Proxy Statement"). This communication does not
constitute an offer to sell or the solicitation of an offer to buy any
securities or a solicitation of any vote or approval, and is not a substitute
for the Proxy Statement or any other document that Monsanto may file with the
SEC or send to its stockholders in connection with the proposed merger.
STOCKHOLDERS OF MONSANTO ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH
THE SEC, INCLUDING THE PROXY STATEMENT, WHEN THEY BECOME AVAILABLE BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors
and security holders will be able to obtain the documents (when available) free
of charge at the SEC's web site, http://www.sec.gov, and Monsanto's website,
www.monsanto.com, and Monsanto stockholders will receive information at an
appropriate time on how to obtain transaction-related documents for free from
Monsanto. In addition, the documents (when available) may be obtained free of
charge by directing a request to Corporate Secretary, Monsanto Company, 800
North Lindbergh Boulevard, St. Louis, Missouri 63167, or by calling (314)
694-8148.


Participants in Solicitation
Monsanto, Bayer and their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies from the holders of
Monsanto common stock in respect of the proposed transaction. Information about
the directors and executive officers of Monsanto is set forth in the proxy
statement for Monsanto's 2016 annual meeting of stockholders, which was filed
with the SEC on December 10, 2015, and in Monsanto's Annual Report on Form 10-K
for the fiscal year ended August 31, 2015, which was filed with the SEC on
October 29, 2015. Other information regarding the participants in the proxy
solicitation and a description of their direct and indirect interests, by
security holdings or otherwise, will be contained in the Proxy Statement and
other relevant materials to be filed with the SEC in respect of the proposed
transaction when they become available.